ENCIRCLE 1-year outcomes: Shaping the future of MR treatment with the SAPIEN M3 system

Supported by Edwards Lifesciences

Summary

Fabien Praz talks with Mayra Guerrero and Henryk Dreger about the ENCIRCLE trial on the Sapien M3 transcatheter mitral valve, which shows strong safety, durable MR reduction, and improved symptoms, quality of life, and LV remodelling. High-quality CT and echo are essential for #TMVR, which is promising in degenerative MR with leaflet calcification. A dedicated MAC registry of 100 patients has finished enrollment, with results expected next year.

This interview was filmed at PCR London Valves 2025: see more videos here.